Marieke J van Son, Max Peters, Deepika Reddy, Taimur T Shah, Feargus Hosking-Jervis, Stephen Robinson, Jan J W Lagendijk, Stephen Mangar, Tim Dudderidge, Stuart McCracken, Richard G Hindley, Amr Emara, Raj Nigam, Raj Persad, Jaspal Virdi, Henry Lewi, Caroline Moore, Clement Orczyk, Mark Emberton, Manit Arya, Hashim U Ahmed, Jochem R N van der Voort van Zyp, Matt Winkler, Alison Falconer
BACKGROUND: For localised prostate cancer, focal therapy offers an organ-sparing alternative to radical treatments (radiotherapy or prostatectomy). Currently, there is no randomised comparative effectiveness data evaluating cancer control of both strategies. METHODS: Following the eligibility criteria PSA < 20 ng/mL, Gleason score ≤ 7 and T-stage ≤ T2c, we included 830 radical (440 radiotherapy, 390 prostatectomy) and 530 focal therapy (cryotherapy, high-intensity focused ultrasound or high-dose-rate brachytherapy) patients treated between 2005 and 2018 from multicentre registries in the Netherlands and the UK...
December 2021: Prostate Cancer and Prostatic Diseases